ClinicalTrials.gg
Not yet recruitingNCT07712861DISON IUpdated Aug 5, 2026

DISON I - Directly Integrated Suction and Optics System for the Treatment of Nephrolithiasis

An interventional study of RIRS with Investigational Device in Kidney Stones, Urolithiasis and Nephrolithiasis, sponsored by Ventaris Surgical Incorporated. Not yet recruiting at 5 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Ventaris Surgical Incorporated · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

A single-arm, multicenter, international, prospective interventional study designed to evaluate the safety and performance of an investigational device during retrograde intrarenal surgery for the treatment of renal calculi.

02

Conditions studied

  • Kidney Stones
  • Urolithiasis
  • Nephrolithiasis

Keywords

  • kidney stones
  • medical device
  • Urological procedure
03

In context

Kidney Calculi

509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.

This study's planned enrollment of 75 is below the median of 86 across 391 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

This is the only study on the registry with Ventaris Surgical Incorporated as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of calyceal and/or renal pelvis calculi
  2. Age from 18 through 85 years
  3. Maximum stone diameter between 0.5cm - 2.0cm as assessed by Non-Contrast CT scan (≤ 2 mm slice thickness) within 90 days prior to treatment
  4. Willing and able to comply with all study requirements
  5. Signs study-specific form

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of calculus of the ureter
  2. ≥ 42
  3. Significant renal impairment: stage 3a CKD or higher ( \<59mL/min)
  4. Active infection, including urinary tract infection
  5. Urological anatomic/congenital abnormalities
  6. Previous history of struvite stone in the same renal unit
  7. Taking anticoagulants that cannot be stopped before and after procedure or known coagulopathy or disorder (except aspirin below 100mg/d)
  8. History of gross hematuria
  9. Solitary functioning kidney
  10. Known allergy to device materials
  11. Any severe illness that would prevent complete study participation or confound study results
  12. Serious concurrent medical conditions such as heart disease (e.g., myocardial infarction within 30 days, congestive heart failure - Class IV), pulmonary disease or uncontrolled diabetes.
  13. History of open-heart surgery, or cardiac arrest \< 180 days prior to the date of
  14. or higher
  15. Taking systemic immune suppressants
  16. Dementia or psychiatric condition that prevents the participant from completing required follow up
  17. to both general and spinal anesthesia
  18. Participating in another study that could affect responses to the study device
  19. Unwilling to accept a transfusion should one be required
  20. Pregnant or considering getting pregnant within the next 3 months
  21. Undergoing bilateral ureteroscopy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Investigational endourological device used during retrograde intrarenal surgery.

    Device: RIRS with Investigational Device

Interventions

  • DeviceRIRS with Investigational Device

    Investigational endourological device used during retrograde intrarenal surgery.

06

What researchers measure

Primary outcomes

  1. Procedure success

    Successful completion of the planned procedure without device-related technical complications.

    Time frame: Intraoperative

  2. Serious Adverse Device Effects (SADEs)

    Serious adverse device effects related to the investigational device.

    Time frame: 30 days post-procedure

  3. Stone-Free Status

    Absence of residual stone fragments on CT imaging

    Time frame: 30 days post-procedure

Secondary outcomes

  1. Stone-Free Categories

    Stone-free status according to predefined categories.

    Time frame: 30 days post-procedure

  2. Intrarenal pressure assessment

    Intrarenal pressure measured during the procedure.

    Time frame: Intraoperative

  3. Procedure duration

    Duration of the surgical procedure.

    Time frame: Intraoperative

  4. Stone clearance

    Amount of stone material removed during the procedure.

    Time frame: Intraoperative

  5. Residual stone burden

    Residual stone burden assessed by imaging.

    Time frame: 30 days post-procedure

  6. Device- or procedure-related adverse event

    Device- or procedure-related adverse event.

    Time frame: From procedure to 12 months post-procedure

  7. Stone-related healthcare utilization

    Healthcare utilization related to recurrent stone symptoms in the treated kidney.

    Time frame: From procedure to 12 months post-procedure

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared because this is an early feasibility study involving a small cohort of participants. The data set is limited and may contain information that could risk re-identification. Summary results and aggregate findings will be published following study completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2028, 22 months later.

Of 199 interventional studies with no phase under Kidney Calculi, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 20, 2026
StartEst.
Oct 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712861
Lead sponsor
Ventaris Surgical Incorporated
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Oct 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Matt Sprinkel
Contact
matt@ventarissurgical.com
+1 650 465 6200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion